SingleTimeMicroneedles

STM Patch specializes in the development of advanced transdermal microneedle patches designed for the programmable burst release of multiple vaccine doses. The company operates in the healthcare and pharmaceutical markets, focusing on improving drug delivery systems for both human and animal applications. STM Patch's technology eliminates the need for booster administrations and cold chain logistics, even for mRNA biologics, thereby reducing the burden on medical personnel and creating no biohazard waste. The patches are also being planned for use in medications, animal health, and certain nutraceutical compounds. The business model revolves around the sale and licensing of its proprietary microneedle platform to pharmaceutical companies and healthcare providers. Revenue is generated through direct sales, partnerships, and licensing agreements. STM Patch aims to enhance global health and wellness by providing equitable access to highly effective vaccines and medications.

Keywords: transdermal microneedles, multi-dose delivery, vaccine deployment, drug delivery, mRNA biologics, healthcare innovation, pharmaceutical technology, supply chain efficiency, animal health, nutraceuticals.